Adherence to disease-modifying antirheumatic drugs and the effects of exposure misclassification on the risk of hospital admission

Arthritis Care and Research

Volumn 62, Issue 5, 2010, Pages 730-734

  Grijalva, Carlos G ^a   Kaltenbach, Lisa ^a   Arbogast, Patrick G ^a   Mitchel Jr , Edward F ^a   Griffin, Marie R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; EPISODE OF CARE; FEMALE; GLUCOCORTICOIDS; HOSPITALIZATION; HUMANS; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; PRODUCT SURVEILLANCE, POSTMARKETING; RETROSPECTIVE STUDIES; TENNESSEE;

EID: 77951758414     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20087     Document Type: Article

References (10)

1. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic diseasemodifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-784.
2. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists. Arthritis Rheum 2007;56:1125-1133 (Pubitemid 46608637)
3. Setoguchi S, Schneeweiss S, Avorn J, Katz JN, Weinblatt ME, Levin R, et al. Tumor necrosis factor-α antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J 2008;156:336-341.
4. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, Society for Rheumatology Biologics Register Control Centre Consortium, et al, for the British Society for Rheumatology Biologics Register. Serious infection following anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007;56:2896-2904.
5. Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF Jr, Griffin MR. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care 2007;45 Suppl 2:S66-76.
6. Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, et al. Anti-tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007;56:1754-1764 (Pubitemid 47110375)
7. Bijlsma JW, Boers M, Saag KG, Furst DE. Glucocorticoids in the treatment of early and late RA. Ann Rheum Dis 2003;62: 1033-1037.
8. Ray WA, Thapa PB, Gideon P. Misclassification of benzodiazepine exposure by use of a single baseline measurement and its effects upon studies of injuries. Pharmacoepidemiol Drug Saf 2002;11:663-669 (Pubitemid 35469361)
9. Solomon DH, Avorn J, Katz JN, Weinblatt ME, Setoguchi S, Levin R, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:3790-3798 (Pubitemid 44955879)
10. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989;84:1074-1078.